A dose-escalation study of combretastatin A4-phosphate in healthy dogs.

Last updated on 22-8-2019 by Anonymous (non vérifié)

Peer reviewed scientific article

SCIENSANO

Mots-clés

Résumé:

Combretastatin A4-Phosphate (CA4P) is a vascular disrupting agent revealing promising results in cancer treatments for humans. The aim of this study was to investigate the safety and adverse events of CA4P in healthy dogs as a prerequisite to application of CA4P in dogs with cancer. Ten healthy dogs were included. The effects of escalating doses of CA4P on physical, haematological and biochemical parameters, systolic arterial blood pressure, electrocardiogram, echocardiographic variables and general wellbeing were characterised. Three different doses were tested: 50, 75 and 100 mg m(-2) . A…

Associated health topics:

QR code

QR code for this page URL